- At the American College of Cardiology, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) highlighted a new data analysis from the SCORED Phase 3 trial of sotagliflozin in Type 2 diabetes and kidney disease patients.
- Sotagliflozin significantly reduced major adverse cardiovascular events (MACE) of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke compared to placebo.
- Also See: Lexicon Announces Loan Facility Of $150M With Oxford Finance To Support Sotagliflozin Commercialization.
- A follow-up analysis of the trial revealed consistent reductions in major adverse cardiovascular events (MACE) in two subgroups —a 21% reduction in MACE in patients with cardiovascular disease and a 26% reduction in MACE in those without CVD.
- In February, Lexicon pulled back a submission for approval in Type 2 diabetes patients with heart failure. That came on top of an FDA rejection for sotagliflozin in 2019 in Type 1 diabetes.
- Price Action: LXRX shares are up 3.11% at $2.32 during the premarket session on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Lexicon Touts New Favorable Data On Sotaglifozin Cardio Data
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks